Daily Intravesical Instillation of 1 mg Nociceptin/Orphanin FQ for the Control of Neurogenic Detrusor Overactivity: A Multicenter, Placebo Controlled, Randomized Exploratory Study

Journal of Urology

Volumn 176, Issue 5, 2006, Pages 2098-2102

  Lazzeri, Massimo ^a   Calò, Girolamo ^b   Spinelli, Michele ^d   Malaguti, Silvia ^d   Guerrini, Remo ^c   Salvadori, Severo ^c   Beneforti, Patrizia ^a   Regoli, Domenico ^b   Turini, Damiano ^a  

^a Department of Urology   (Italy)

^b Neuroscience Center   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY OF FERRARA   (Italy)

Author keywords

afferent; bladder; neurogenic; neurons; nociceptin receptor; spinal cord injuries; urinary incontinence

Indexed keywords

NOCICEPTIN; PLACEBO;

ADULT; ARTICLE; AUTONOMIC DYSREFLEXIA; BLADDER CAPACITY; BLADDER PRESSURE; BURNING SENSATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTOMETRY; DETRUSOR DYSSYNERGIA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEASIBILITY STUDY; FEMALE; HUMAN; INTERMITTENT CATHETERIZATION; MALE; MICTURITION; MULTICENTER STUDY; NEUROGENIC BLADDER; OVERACTIVE BLADDER; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; URINE INCONTINENCE; URINE VOLUME;

ADMINISTRATION, INTRAVESICAL; ADULT; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; OPIOID PEPTIDES; URINARY BLADDER, NEUROGENIC; URINARY BLADDER, OVERACTIVE;

EID: 33750326776     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2006.07.025     Document Type: Article

References (20)

1. Yoshimura N., and Chancellor M.B. Current and future pharmacological treatment for overactive bladder. J Urol 168 (2002) 1897
2. Chapple C., Khullar V., Gabriel Z., and Dooley J.A. The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. Eur Urol 48 (2005) 5
3. Chancellor M.B., and de Groat W.C. Intravesical capsaicin and resiniferatoxin therapy: spicing up the ways to treat the overactive bladder. J Urol 162 (1999) 3
4. Lazzeri M., Spinelli M., Zanollo A., and Turini D. Intravesical vanilloids and neurogenic incontinence: ten years experience. Urol Int 72 (2004) 145
5. Meunier J.C., Mollereau C., Toll L., Suaudeau C., Moisand C., Alvinerie P., et al. Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature 377 (1995) 532
6. Reinscheid R.K., Nothacker H.P., Bourson A., Ardati A., Henningsen R.A., Bunzow J.R., et al. Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor. Science 270 (1995) 792
7. Calò G., Guerrini R., Rizzi A., Salvadori S., and Regoli D. Pharmacology of nociceptin and its receptor: a novel therapeutic target. Br J Pharmacol 129 (2000) 1261
8. Cox B.M., Chavkin C., Christie M.J., Civelli O., Evans C., Hamon M.D., et al. Opioid receptors. In: Girdlestone D. (Ed). The IUPHAR Compendium of Receptor Characterization and Classification (2002), IUPHAR Media Ltd, London 321-333
9. Lecci A., Giuliani S., Meini S., and Maggi C.A. Nociceptin and the micturition reflex. Peptides 21 (2000) 1007
10. Lazzeri M., Calò G., Spinelli M., Guerrini R., Beneforti P., Sandri S., et al. Urodynamic and clinical evidence of acute inhibitory effects of intravesical nociceptin/orphanin FQ on detrusor overactivity in humans: a pilot study. J Urol 166 (2001) 2237
11. Lazzeri M., Calo G., Spinelli M., Guerrini R., Salvadori S., Beneforti P., et al. Urodynamic effects of intravesical nociceptin/orphanin FQ in neurogenic detrusor overactivity: a randomized, placebo-controlled, double-blind study. Urology 61 (2003) 946
12. Guerrini R., Calò G., Rizzi A., Bianchi C., Lazarus L.H., Salvadori S., et al. Address and message sequences for the nociceptin receptor: a structure-activity study of nociceptin-(1-13)-peptide amide. J Med Chem 40 (1997) 1789
13. The standardisation of terminology in lower urinary tract function. Available from http://icsoffice.org
14. Herbison P., Hay-Smith J., Ellis G., and Moore K. Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. BMJ 326 (2003) 841
15. Brendler C.B., Radebaugh L.C., and Mohler J.L. Topical oxybutynin chloride for relaxation of dysfunctional bladders. J Urol 141 (1989) 1350
16. Madersbacher H., and Jilg G. Control of detrusor hyperreflexia by the intravesical instillation of oxybutynine hydrochloride. Paraplegia 29 (1991) 84
17. Weese D.L., Roskamp D.A., Leach G.E., and Zimmern P.E. Intravesical oxybutynin chloride: experience with 42 patients. Urology 41 (1993) 527
18. Saito M., Tabuchi F., Otsubo K., and Miyagawa I. Treatment of overactive bladder with modified intravesical oxybutynin chloride. Neurourol Urodyn 19 (2000) 683
19. Di Stasi S.M., Giannantoni A., Massoud R., Cortese C., Vespasiani G., and Micali F. Electromotive administration of oxybutynin into the human bladder wall. J Urol 158 (1997) 228
20. Fowler C.J., Jewkes D., McDonald W.I., Lynn B., and de Groat W.C. Intravesical capsaicin for neurogenic bladder dysfunction. Lancet 339 (1992) 1239